AU2001267882A1 - Preventives and remedies for diseases in association with demyelination - Google Patents

Preventives and remedies for diseases in association with demyelination

Info

Publication number
AU2001267882A1
AU2001267882A1 AU2001267882A AU6788201A AU2001267882A1 AU 2001267882 A1 AU2001267882 A1 AU 2001267882A1 AU 2001267882 A AU2001267882 A AU 2001267882A AU 6788201 A AU6788201 A AU 6788201A AU 2001267882 A1 AU2001267882 A1 AU 2001267882A1
Authority
AU
Australia
Prior art keywords
diseases
pharmaceutical
demyelination
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001267882A
Inventor
Hiroaki Asou
Makoto Sugawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Tokyo Metropolitan Institute of Gerontology (TMIG)
Original Assignee
TOKYO METROPOLITAN INST OF GER
Chugai Pharmaceutical Co Ltd
Tokyo Metropolitan Institute of Gerontology (TMIG)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TOKYO METROPOLITAN INST OF GER, Chugai Pharmaceutical Co Ltd, Tokyo Metropolitan Institute of Gerontology (TMIG) filed Critical TOKYO METROPOLITAN INST OF GER
Publication of AU2001267882A1 publication Critical patent/AU2001267882A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A pharmaceutical for prevention and treatment of demyelination-associated neural function impairing diseases, the pharmaceutical containing erythropoietin as an active ingredient, and a method for prevention and treatment of the diseases are provided. The preventive and therapeutic pharmaceutical and method of the present invention protectively act on the survival of oligodendrocytes, which form a myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease, diseases involving demyelination. The pharmaceutical and method also promote maturation of undifferentiated oligodendrocytes present in the brain, activating remyelination. Through these mechanisms, the pharmaceutical and method can prevent and treat demyelination-associated neural function impairing diseases. <IMAGE>
AU2001267882A 2000-06-30 2001-06-29 Preventives and remedies for diseases in association with demyelination Abandoned AU2001267882A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-199421 2000-06-30
JP2000199421 2000-06-30
PCT/JP2001/005641 WO2002002135A1 (en) 2000-06-30 2001-06-29 Preventives and remedies for diseases in association with demyelination

Publications (1)

Publication Number Publication Date
AU2001267882A1 true AU2001267882A1 (en) 2002-01-14

Family

ID=18697441

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001267882A Abandoned AU2001267882A1 (en) 2000-06-30 2001-06-29 Preventives and remedies for diseases in association with demyelination

Country Status (7)

Country Link
US (1) US8039253B2 (en)
EP (1) EP1295604B1 (en)
JP (1) JP5053499B2 (en)
AT (1) ATE444077T1 (en)
AU (1) AU2001267882A1 (en)
DE (1) DE60140054D1 (en)
WO (1) WO2002002135A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US9006155B2 (en) 2005-09-09 2015-04-14 Halliburton Energy Services, Inc. Placing a fluid comprising kiln dust in a wellbore through a bottom hole assembly
US9809737B2 (en) 2005-09-09 2017-11-07 Halliburton Energy Services, Inc. Compositions containing kiln dust and/or biowaste ash and methods of use
US8505630B2 (en) 2005-09-09 2013-08-13 Halliburton Energy Services, Inc. Consolidating spacer fluids and methods of use
US8403045B2 (en) 2005-09-09 2013-03-26 Halliburton Energy Services, Inc. Settable compositions comprising unexpanded perlite and methods of cementing in subterranean formations
US8307899B2 (en) 2005-09-09 2012-11-13 Halliburton Energy Services, Inc. Methods of plugging and abandoning a well using compositions comprising cement kiln dust and pumicite
US8505629B2 (en) 2005-09-09 2013-08-13 Halliburton Energy Services, Inc. Foamed spacer fluids containing cement kiln dust and methods of use
US8555967B2 (en) 2005-09-09 2013-10-15 Halliburton Energy Services, Inc. Methods and systems for evaluating a boundary between a consolidating spacer fluid and a cement composition
US9676989B2 (en) 2005-09-09 2017-06-13 Halliburton Energy Services, Inc. Sealant compositions comprising cement kiln dust and tire-rubber particles and method of use
US9051505B2 (en) 2005-09-09 2015-06-09 Halliburton Energy Services, Inc. Placing a fluid comprising kiln dust in a wellbore through a bottom hole assembly
US8333240B2 (en) 2005-09-09 2012-12-18 Halliburton Energy Services, Inc. Reduced carbon footprint settable compositions for use in subterranean formations
US9023150B2 (en) 2005-09-09 2015-05-05 Halliburton Energy Services, Inc. Acid-soluble cement compositions comprising cement kiln dust and/or a natural pozzolan and methods of use
US8281859B2 (en) 2005-09-09 2012-10-09 Halliburton Energy Services Inc. Methods and compositions comprising cement kiln dust having an altered particle size
US8297357B2 (en) * 2005-09-09 2012-10-30 Halliburton Energy Services Inc. Acid-soluble cement compositions comprising cement kiln dust and/or a natural pozzolan and methods of use
US8672028B2 (en) 2010-12-21 2014-03-18 Halliburton Energy Services, Inc. Settable compositions comprising interground perlite and hydraulic cement
US8950486B2 (en) 2005-09-09 2015-02-10 Halliburton Energy Services, Inc. Acid-soluble cement compositions comprising cement kiln dust and methods of use
US8522873B2 (en) 2005-09-09 2013-09-03 Halliburton Energy Services, Inc. Spacer fluids containing cement kiln dust and methods of use
US9150773B2 (en) 2005-09-09 2015-10-06 Halliburton Energy Services, Inc. Compositions comprising kiln dust and wollastonite and methods of use in subterranean formations
US8327939B2 (en) 2005-09-09 2012-12-11 Halliburton Energy Services, Inc. Settable compositions comprising cement kiln dust and rice husk ash and methods of use
US8609595B2 (en) 2005-09-09 2013-12-17 Halliburton Energy Services, Inc. Methods for determining reactive index for cement kiln dust, associated compositions, and methods of use
DE102006004008A1 (en) * 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
JPWO2008023725A1 (en) 2006-08-22 2010-01-14 中外製薬株式会社 Prophylactic and / or therapeutic agent for peripheral neuropathy
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
WO2010092419A1 (en) * 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
US20170304367A1 (en) * 2014-10-29 2017-10-26 University Of Utah Research Foundation Methods of treating hypoxia-associated optical conditions with cartilage oligo matrix protein-angiopoietin 1 (comp-ang1)
CN115501227B (en) * 2021-08-02 2023-09-19 中山大学·深圳 Application of compound in preparing medicine for preventing and treating demyelinating diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732889A (en) 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
JP3537151B2 (en) * 1991-12-26 2004-06-14 中外製薬株式会社 Prevention and treatment of diseases due to cerebral dysfunction
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US7410941B1 (en) * 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
CN1607957B (en) 1999-04-13 2012-10-10 肯尼思S.沃伦协会有限公司 Modulation of excitable tissue function by peripherally administered erythropoietin
JP2001010972A (en) * 1999-06-30 2001-01-16 Masahiro Sakanaka Cytoprotective agent comprising peptide relating to prosaposin

Also Published As

Publication number Publication date
US8039253B2 (en) 2011-10-18
EP1295604B1 (en) 2009-09-30
WO2002002135A1 (en) 2002-01-10
JP5053499B2 (en) 2012-10-17
DE60140054D1 (en) 2009-11-12
ATE444077T1 (en) 2009-10-15
EP1295604A4 (en) 2005-04-27
EP1295604A1 (en) 2003-03-26
US20050032682A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
AU2001267882A1 (en) Preventives and remedies for diseases in association with demyelination
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
HK1029043A1 (en) Remedy for neurodegenerative diseases.
WO2004073614A3 (en) Combination therapy for the treatment of immunoinflammatory disorders
AU2002357311A1 (en) Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
IL159299A0 (en) Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
EP0722737A4 (en) Remedy for cranial nerve disorder
DE69825292D1 (en) USE OF INOSINE FOR PRODUCING A MEDICINE FOR STIMULATING AXON GROWTH OF CNS NEURONES
WO2005067908A3 (en) Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
DE69819110D1 (en) A medicine to treat obesity and improve lipid metabolism
EP2277528A3 (en) Use of VEGF and homologues to treat neuron disorders
WO2003068147A3 (en) Treatments for neurotoxicity in alzheimer’s disease
WO2000057865A3 (en) Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
WO2002100836A3 (en) Compounds, compositions and methods for modulating beta-amyloid production
ATE157871T1 (en) MEDICINAL PRODUCTS FOR THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF DISEASES CAUSED BY HYPERPLASIA OF SMOOTH MUSCLE CELLS
WO2002101392A3 (en) Methods for treating disorders of the nervous and reproductive systems
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
DE69724490D1 (en) Substance used to treat alopecia
WO2006055381A3 (en) Prodrugs of (2r)-2-propyloctanoic acid for treatment of stroke
IT1255179B (en) AZACICLO AND AZABICICLO ALCHILIDEN IDROSSILAMINE
DE60004093D1 (en) PHARMACEUTICAL COMPOSITION WHICH CONTAINS RILUZOL AND GABAPENTIN FOR THE TREATMENT OF MOTONEURONAL DISEASES
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer&#39;s disease
WO2024108179A3 (en) 2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement